Related Experiment Video
Updated: Jan 22, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Remibrutinib: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
None:
Remibrutinib (Rhapsido®) is an orally administered, selective Bruton's tyrosine kinase (BTK) inhibitor being developed by Novartis for the treatment of chronic spontaneous urticaria (CSU) as well as other immune-mediated disorders. On 30 September 2025 remibrutinib received its first approval in the USA for treatment of CSU in adult patients who remain symptomatic despite H1-antihistamine treatment. It has subsequently been approved for use in the same indication in China and is under regulatory review in the EU and Japan. This article summarises the milestones in the development of remibrutinib leading to this first approval for CSU in adult patients who remain symptomatic despite H1-antihistamine treatment.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Obedience
Ethics in Research

